iLine Microsystems

Executive Summary

iLine Microsystems is a Spanish biotechnology company specializing in point-of-care in vitro diagnostics for hemostasis, with a primary focus on oral anticoagulant therapy monitoring. Founded in 2007 and headquartered in Barcelona, the company has developed the microINR system, a family of coagulometers and disposable chips that leverage proprietary microfluidic and lab-on-a-chip technology. These devices enable user-friendly, connected testing for both healthcare professionals and patients, addressing the growing need for decentralized anticoagulation management. iLine's platform aims to improve patient outcomes by enabling frequent, convenient INR monitoring, reducing the risk of thrombotic or bleeding events associated with vitamin K antagonist therapy. The global shift toward point-of-care testing and personalized medicine presents a significant opportunity for iLine Microsystems. With an aging population and increasing prevalence of atrial fibrillation, the demand for effective anticoagulation management is rising. iLine's technology offers advantages in portability, ease of use, and connectivity, positioning it well against traditional laboratory-based methods and competitor devices. The company's established presence in Europe and potential expansion into emerging markets could drive growth. However, it operates in a competitive landscape with major players like Roche and Abbott. iLine's ability to secure regulatory approvals, forge distribution partnerships, and continuously innovate will be critical to its success.

Upcoming Catalysts (preview)

• H2 2026CE-IVDR Certification for microINR System80% success
• H1 2027Distribution Partnership in Europe60% success
• Q4 2026Launch of Next-Generation Connected Coagulometer70% success